Positive Preclinical Proof-of-Concept Results of BB-FA in Mice Model of Friedreich’s Ataxia

Positive Preclinical Proof-of-Concept Results of BB-FA in Mice Model of Friedreich’s Ataxia. BioBlast Announced Preclinical Data and Pipeline Updates. April 14, 2015

BioBlast (NasdaqGM: ORPN) announced positive in vitro and in vivo results from a therapy for Friedreich’s ataxia based on the mitochondria-targeting platform, providing support for further clinical development.